PT  - JOURNAL ARTICLE
AU  - Chaudhury, Sidhartha
AU  - MacGill, Randall S.
AU  - Early, Angela M.
AU  - Bolton, Jessica S.
AU  - King, C. Richter
AU  - Locke, Emily
AU  - Pierson, Tony
AU  - Wirth, Dyann F.
AU  - Neafsey, Daniel E.
AU  - Bergmann-Leitner, Elke S.
TI  - Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine
AID  - 10.1101/2020.11.15.20232033
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.15.20232033
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.15.20232033.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.15.20232033.full
AB  - The circumsporozoite protein (CSP) is the main surface antigen of malaria sporozoites and a prime vaccine target. Responses induced by the CSP-based RTS,S vaccine towards the polymorphic C-terminal region of P.falciparum-CSP raise concerns that vaccines using single alleles may have lower efficacy against genotypic variants. We characterized the extent of C-terminal cross-reactivity of antibodies induced by RTS,S (based on the 3D7 allele) with variants representing seven circulating field isolates through a novel HTS-multiplex assay for screening closely related peptides. Reactivity to variants showed approximately 30-fold reduction in recognition relative to 3D7. The degree of reduced cross-reactivity,ranging from 21 to 69-fold, directly correlated with the number of polymorphisms between variants and 3D7. Surprisingly, protection assessed by challenge with 3D7 parasites was strongly associated with higher C-terminal antibody breadth suggesting that C-terminal specific avidity or fine-specificity may play a role in RTS,S/AS01B-mediated protection and that breadth of C-terminal CSP-specific antibody responses may be a marker of protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by PATH-Malaria Vaccine Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting the views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25. This paper has been approved for public release with unlimited distribution.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analysis scripts used in this study were written in R and are available freely for download at https:// github.com/BHSAI/immstat. Experimental data and protocols are made available upon request to corresponding author. ASAdjuvant system (GSK nomenclature)CHMIControlled human malaria infectionCSPCircumsporozoite proteinECLIAElectro-chemiluminescenceMLSMean luminescence signalMSDMesoscale DiagnosticsNKNatural killer cellsRTS,SScientific name of malaria vaccine indicating the vaccine componentsTh_RHelper T regionTSRThrombospondin repeat